The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study
Open Access
- 27 July 2021
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 24 (11), 1634-1642
- https://doi.org/10.1016/j.jval.2021.05.009
Abstract
No abstract availableKeywords
Funding Information
- NIHR Trainees Coordinating Centre (DRF-2016-09-119)
- National Institute for Health Research
This publication has 15 references indexed in Scilit:
- Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsPharmacoEconomics, 2019
- How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017International Journal of Technology Assessment in Health Care, 2019
- Estimating the loss of lifetime function using flexible parametric relative survival modelsBMC Medical Research Methodology, 2019
- Using simulation studies to evaluate statistical methodsStatistics in Medicine, 2019
- A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?Journal of Medical Economics, 2018
- Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and ExtrapolationPharmacoEconomics, 2017
- flexsurv: A Platform for Parametric Survival Modeling inRJournal of Statistical Software, 2016
- Current Estimates of the Cure Fraction: A Feasibility Study of Statistical Cure for Breast and Colorectal CancerJNCI Monographs, 2014
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level DataMedical Decision Making, 2013
- Estimating and modeling the cure fraction in population-based cancer survival analysisBiostatistics, 2006